1Bhana N,Goa K L,McClellan K J. Dexmedetomidine[J].Drugs,2000,(02):263-268.
2Ríha H,Kotulák T,B(r)ezina A. Comparison of the effects of ketamine-dexmedetomidine and sevoflurane-sufentanil anesthesia on cardiac biomarkers after cardiac surgery:an observational study[J].Physiological Research,2012,(01):63-72.
3Sanders R D,Sun P,Patel S. Dexmedetomidine provides cortical neuroprotection:impact on anaesthetic-induced neuroapoptosis in the rat developing brain[J].Acta Anaesthesiologica Scandinavica,2010,(06):710-716.
4Sato K,Kimura T,Nishikawa T. Neuroprotective effects of a combination of dexmedetomidine and hypothermia after incomplete cerebral ischemia in rats[J].Acta Anaesthesiologica Scandinavica,2010,(03):377-382.
5Shi Q Q,Wang H,Fang H. Dose-response and mechanism of protective functions of selective alpha-2 agonist dexmedetomidine on acute lung injury in rats[J].Saudi Medical Journal,2012,(04):375-381.
6Zhang X Y,Liu Z M,Wen S H. Dexmedetomidine administration before,but not after,ischemia attenuates intestinal injury induced by intestinal ischemia-reperfusion in rats[J].Anesthesiology,2012,(05):1035-1046.
7Paris A,Tonner P H. Dexmedetomidine in anaesthesia[J].Current Opinion in Anaesthesiology,2005,(04):412-418.doi:10.1097/01.aco.0000174958.05383.d5.
8Chrysostomou C,Schmitt C G. Dexmedetomidine:sedation,analgesia and beyond[J].Expert Opin Drug Metab Toxicol,2008,(05):619-627.
9Dyck J B,Shafer S L. Dexmedetomidine pharmacokinetics and pharmacodynamics[J].Anesth Pharm Rev,1993.238-245.
10Hsing C H,Lin C F,So E. Alpha-2 adrenoceptor agonist-dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5[J].American Journal of Physiology-Renal Physiology,2012.
同被引文献71
1Green L, Lawrie AS, Patel R, et al. The effect of total hip/knee replace- ment surgery and prophylactic dabigatran on thrombin generation and coag- ulation parameters [ J ]. Thromb Res, 2012,130 (5) : 775 - 779.
2Verhamme P, Gunn S, Sonesson E, et al. Single - dose TB - 402 or rivarox- aban for the prevention of venous thromboembolism after total hip replace- ment. A randomised, controlled trial [ J ]. Thromb Haemost, 2013,109 (6) : 1 091 - 1 098.
3Shimoyama Y, Sawai T, Tatsumi S, et al. Perioperative risk factors for deep vein thrombosis after total hip arthroplasty or total knee arthroplasty[J]. J Clin Anesth,2012,24(7) : 531 - 536.
4Warwick D, Rosencher N. The "critical thrombosis period" in major ortho- pedic surgery: when to start and when to stop prophylaxis[J]. Clin Appl Thromb Hemost,2010,16(4) : 394 - 405.
5Dager WE. Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and chal- lenges remaining [J]. Ann Pharmaeother, 2012,46 ( 1 ) : 79 - 88.
6Ihmsen H, Saari TI. Dexmedetomidine. Pharrnacokinetics and pharmacody- namics [J]. Anaesthesist,2012 ,61 (12): 1 059 - 1 066.
8MacLaren R. Immunosedation: a consideration for sepsis. Crit Care,2009,13 (5) : 191.
9Sulaiman S, Kathekeyan RB, Vakamudi M, et al. The effects of dexmedetomidine on attenuation of stress re- sponse to endotracheal intubation in patients undergo- ing elective off-pump coronary artery bypass grafting [J]. Ann Card Anaesth, 2012, 15(1) : 39-43.
10Hofer S, Steppan J, Wagner T, et al. Central sympa- tholytics prolong survival in experimental sepsis [ J ]. Crit Care, 2009, 13(1) : R11.
